• Product NameMitiglinide calcium
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityMitiglinide is a drug for the treatment of type 2 diabetes. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.
• Target NamePotassium Channel antagonist
• CAS No. 207844-01-7
• Calculated MW 704.91
• Formulation C38H52CaN2O8
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)[O-].C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)[O-].O.O.[Ca+2]
  Pathways:Membrane transporter/Ion channel
  Receptor:Potassium Channel
  Boling pt:
  Melting pt:179-185C
  Solubility:DMSO: 10 mM
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Malaisse WJ. Expert Opin PharmacOthers. 2008 Oct;9(15):2691-8.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting